Navitoclax
Cat. No.：YN270019
CAS No. ：923564-51-6
| 产品名称: | Navitoclax |
| CAS No.: | 923564-51-6 |
| Chemical Name: | 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-benzamide |
| Synonyms: | ABT-263 |
| 分子量: | 974.61 |
| 分子式: | C₄₇H₅₅ClF₃N₅O₆S₃ |
| SMILES: | O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Navitoclax (ABT-263) 是有效，可口服的Bcl-2抑制剂，可与Bcl-xL，Bcl-2， Bcl-w等多种Bcl-2家族蛋白结合，Ki值小于 1 nM。 |
| IC50和靶点: | [{name:"Bcl-W:1 nM (Ki)"},{name: "Bcl-xL:1 nM (Ki)"},{name: "Bcl-2:1 nM (Ki)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Tse, C., Shoemaker, A.R., Adickes, J., et al.ABT-263: A potent and orally bioavailable Bcl-2 family inhibitorCancer Res.68(9),3421-3428(2008)
Bulanova, D., Ianevski, A., Bugai, A., et al.Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteinsViruses9(10),E271(2017)
Shoemaker, A.R., Mitten, M.J., Adickes, S., et al.Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft modelsClin. Cancer Res.14(11),3268-3277(2008)
